NDAORALSOLUTION
Approved
Apr 2025
Lifecycle
Launch
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
LOPRESSOR (metoprolol tartrate) by Rubicon Biotechnology is 12. First approved in 2025.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Lopressor (metoprolol tartrate) is a beta-1 selective adrenergic receptor blocking agent used to treat hypertension, angina pectoris, and heart failure. It works by blocking catecholamine-induced increases in heart rate, myocardial contraction velocity, and blood pressure, thereby reducing cardiac oxygen demand. The drug is available as an oral solution formulation.
$0.37MPart D
LaunchEarly-stage launch with modest Part D utilization suggests opportunity for market expansion and team growth as awareness increases among prescribers.
Mechanism of Action
12.1 Mechanism of Action Metoprolol is a beta 1 -selective (cardioselective) adrenergic receptor blocking agent. This preferential effect is not absolute, however, and at higher plasma concentrations, metoprolol also inhibits beta 2 -adrenoreceptors, chiefly located in the bronchial and vascular…
Worked on LOPRESSOR at Rubicon Biotechnology? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.